HIM
RPRX icon

Hillsdale Investment Management’s Royalty Pharma RPRX Stock Holding History

Hillsdale Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
32,580
+3,930
+14% +$205K 0.04% 318
2026
Q1 		$1.37M Buy
28,650
+4,500
+19% +$197K 0.04% 328
2025
Q4 		$933K Buy
24,150
+23,700
+5,267% +$904K 0.03% 383
2025
Q3 		$15.9K Sell
450
-23,600
-98% -$854K ﹤0.01% 525
2025
Q2 		$867K Sell
24,050
-700
-3% -$23.2K 0.03% 324
2025
Q1 		$770K Buy
24,750
+500
+2% +$15.8K 0.04% 286
2024
Q4 		$619K Buy
24,250
+600
+3% +$15.9K 0.03% 338
2024
Q3 		$669K Buy
23,650
+3,500
+17% +$96.9K 0.05% 326
2024
Q2 		$531K Hold
20,150
– – 0.04% 325
2024
Q1 		$612K Buy
20,150
+2,900
+17% +$85.5K 0.05% 280
2023
Q4 		$485K Buy
17,250
+1,850
+12% +$50.8K 0.04% 314
2023
Q3 		$418K Buy
15,400
+2,600
+20% +$77.2K 0.04% 309
2023
Q2 		$393K Buy
12,800
+1,300
+11% +$44K 0.04% 295
2023
Q1 		$414K Hold
11,500
– – 0.04% 367
2022
Q4 		$454K Buy
11,500
+100
+0.9% +$4.17K 0.04% 368
2022
Q3 		$458K Buy
+11,400
New +$487K 0.04% 343

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's RPRX Position: Q2 2026 in Review

Hillsdale Investment Management increased its Royalty Pharma (RPRX) stake by 14% in Q2 2026, buying an estimated $205K and bringing the position to 32,580 shares worth $1.83M. The position accounts for 0.04% of the portfolio, ranked #318.

Hillsdale Investment Management first reported a position in RPRX in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Hillsdale Investment Management held 32,580 shares of Royalty Pharma worth $1.83M as of Q2 2026.
  • Hillsdale Investment Management bought 3,930 Royalty Pharma shares in Q2 2026, an estimated $205K.
  • Royalty Pharma made up 0.04% of Hillsdale Investment Management's portfolio in Q2 2026, its #318 holding.
  • Hillsdale Investment Management first reported a position in Royalty Pharma in Q3 2022 and has held it in 16 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.